Over The Counter Medicines

duBUSINESS INSIGHTS

The Pharmaceutical OTC Outlook to 2010
by Kate Bradley

The life cycle of a pharmaceutical product with and without a switch to OTC status

opportunity for switching

Sales

Time
Product launch
ethical sales of product OTC sales of product

Patent expiry

"Success within the OTC market can extend the life of an Rx product that has been switched. In order toincrease the likelihood that a product is successful post-switch, the manufacturer will often switch to OTC status as the product approaches patent expiry, rather than afterwards."
The Pharmaceutical OTC Outlook to 2010

Business Insights
Business Insights is a series of management reports designed to help you make informed, timely business decisions. We understand the problems facing today'smanagers in taking your business' into the next millennium, and appreciate the importance of the role of accurate, up-to-date, incisive market and company analysis. We help you to crystallise your business decision making. Business Insights’ reports are authored by independent experts in their fields and offer results from our unique primary research methodology. Our authors' leading positionsallow them to interview key industry executives and to quantify which issues will be of greatest strategic significance in an industry's future. The results of our analysis and recommendations will help you to evaluate the impact of these issues on your business, and plan to position yourselves to take the greatest advantage of opportunities which will arise in tomorrow’s commercial environment. Thestrength of our Healthcare research and analysis function is derived from its access to unparalleled databases and libraries of information, its proprietary analytic techniques and its people. Staff are drawn from a very wide set of disciplines including strategic consultancy, medicine, the pharmaceutical industry, IT consultancy, accountancy and legal practice. They have a large variety offunctional skill bases, from technician to sales and marketing, and collectively speak numerous different European, Asian and other languages.

Trusted by blue chip companies
Our client list includes:
3M Abbott Affymetrix Agouron Allergan Alza Ares Serono Nycomed Amersham Amgen Andersen Consulting Astra BASF Bausch & Lomb Baxter Bayer Beaufour Ipsen BioChem Pharma Biochemie Biogal-Teva BiogenBoehringer Ingelheim Boots Bristol-Myers Squibb British Biotech Byk Gulden Cardinal Health Chiesi Chiron Chiroscience Chugai Daiichi Eisai Elan Eli Lilly Fournier Fujisawa Gehe Glaxo Wellcome Hoechst Marion Roussel Hoffman La Roche Immuno AG IPSEN Janssen Johnson & Johnson Knoll LEK Lipha Lundbeck Merck KGaA Merck & Co Novartis Novo Nordisk Pfizer Pharmachemie Pharmacia & Upjohn Pliva Procter & GambleRanbaxy Recordati Rhône-Poulenc Rorer Roche Sanofi Schering-Plough Schwarz Searle SmithKline Beecham Solvay Synthélabo Takeda Tanabe Teva Warner-Lambert Zeneca

Your guide to success
This report focuses on the development of the OTC market in terms of the current dynamics and future evolution. Within this framework, detailed analysis of the drivers for growth and the barriers to expansion isconducted, covering pharmaceutical to OTC switches, changes in political climate and the development of OTC industry as a cost containment tool. The major players in the OTC market are identified and profiled, along with the products that drive these companies. Individual markets are also examined. These include the US, as the leading
“The switching of ethical drugs to OTC status has been drivenprimarily by the commercial interests of individual pharmaceutical companies and by the desire of individual governments to curtail the growth of their national drug bills”.
The Pharmaceutical OTC Outlook to 2010

Factors affecting the growth of the OTC market within different geographic regions

Political, social and economic climate; • stability of the economy; • education status of the...